Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLS-5300 (INO-4700) in healthy volunteers
NCT02670187Phase 1Completed
- Sponsor
- GeneOne Life Science, Inc.
- Start
- Feb 2016
- Primary completion
- May 2017
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of INO-4700 in Middle East respiratory syndrome (MERS) (3 arms), sponsored by GeneOne Life Science, Inc. Primary endpoints: Mean change from baseline in safety laboratory measures at Week 60, Incidence of solicited adverse events after vaccination at Week 60 and 2 more. Started Feb 2016; status: completed.
02
Drugs
INO-4700
03
Conditions
Middle East respiratory syndrome (MERS)
Beyond the preview
Go deeper on NCT02670187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02670187.